Show simple item record

dc.contributor.authorEvans, D Gareth R
dc.contributor.authorHowell, Anthony
dc.date.accessioned2009-06-22T14:04:04Z
dc.date.available2009-06-22T14:04:04Z
dc.date.issued2007-09
dc.identifier.citationBreast cancer risk-assessment models. 2007, 9 (5):213 Breast Cancer Res.en
dc.identifier.issn1465-542X
dc.identifier.pmid17888188
dc.identifier.doi10.1186/bcr1750
dc.identifier.urihttp://hdl.handle.net/10541/71124
dc.description.abstractThere are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2? What are her risks of developing breast cancer with or without such a mutation? These risks taken together with the risks and benefits of the intervention will then determine whether an intervention is appropriate. A number of models have been developed for assessing these risks with varying degrees of validation. With further improvements in our knowledge of how to integrate risk factors and to eventually integrate further genetic variants into these models, we are confident we will be able to discriminate with far greater accuracy which women are most likely to develop breast cancer.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshBreast Neoplasms
dc.subject.meshFemale
dc.subject.meshGenes, BRCA1
dc.subject.meshGenes, BRCA2
dc.subject.meshHumans
dc.subject.meshModels, Genetic
dc.subject.meshRisk Assessment
dc.titleBreast cancer risk-assessment models.en
dc.typeArticleen
dc.contributor.departmentClinical Genetics, Academic Unit of Medical Genetics and Regional Genetics Service, St Mary's Hospital, Manchester M13 0JH, UK. Gareth.evans@cmmc.nhs.uken
dc.identifier.journalBreast Cancer Researchen
html.description.abstractThere are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2? What are her risks of developing breast cancer with or without such a mutation? These risks taken together with the risks and benefits of the intervention will then determine whether an intervention is appropriate. A number of models have been developed for assessing these risks with varying degrees of validation. With further improvements in our knowledge of how to integrate risk factors and to eventually integrate further genetic variants into these models, we are confident we will be able to discriminate with far greater accuracy which women are most likely to develop breast cancer.


This item appears in the following Collection(s)

Show simple item record